2.76
+0.04(+1.47%)
Currency In USD
| Previous Close | 2.72 |
| Open | 2.74 |
| Day High | 3.05 |
| Day Low | 2.55 |
| 52-Week High | 7.92 |
| 52-Week Low | 1.71 |
| Volume | 409,678 |
| Average Volume | 1.3M |
| Market Cap | 29.43M |
| PE | -1.76 |
| EPS | -1.57 |
| Moving Average 50 Days | 2.97 |
| Moving Average 200 Days | 4.76 |
| Change | 0.04 |
If you invested $1000 in Serina Therapeutics, Inc. (SER) since IPO date, it would be worth $28.52 as of February 03, 2026 at a share price of $2.76. Whereas If you bought $1000 worth of Serina Therapeutics, Inc. (SER) shares 5 years ago, it would be worth $37.52 as of February 03, 2026 at a share price of $2.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
GlobeNewswire Inc.
12 hours ago
“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and in
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
GlobeNewswire Inc.
Jan 28, 2026 9:12 PM GMT
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American:
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity
GlobeNewswire Inc.
Jan 15, 2026 9:30 PM GMT
HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Pa